

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

**Application Number**

Not Yet Assigned

**Filing Date**

April 7, 2006

**First Named Inventor**

Avolio, et al.

## Group Art Unit

**Not Yet Assigned**

**Examiner Name**

**Not Yet Assigned**

Sheet

**1**

of

2

Attorney Docket Number

IT0061P

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	3	EP	1162196	A1	Japan Tobacco Inc. (Corresponds to WO01/47883)	12/12/2001
	4	WO	02/04425	A2	Boehringer Ingelheim (Canada) Ltd.	01/17/2002
	5	EP	1400241	A1	Japan Tobacco Inc. (Corresponds to WO03/000254)	03/24/2004
	6	WO	03/010140	A2	Boehringer Ingelheim (Canada) Ltd.	02/06/2003
	7	WO	03/010141	A2	Boehringer Ingelheim (Canada) Ltd.	02/06/2003
	8	WO	04/065367	A1	Boehringer Ingelheim International GMBH	08/05/2004

**Examiner  
Signature**

/Sun Jae Loewe/

Date  
Considered

02/22/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

**COMPLETE IF KNOWN**

## NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*Cite  
No.

**Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.**

9

10

11

12

13

14

15

Von Angerer, E., et al., "2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity", Journal of Medicinal Chemistry, Vol. 30, No. 1, pp. 131-136 (1987)
Traxler, P. M., et al., "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", Journal of Medicinal Chemistry, Vol. 39, No. 12, pp. 2285-2292 (1996)
Chi, S. M., et al., "Palladium-catalyzed functionalization of 5- and 7-azaindoles", Tetrahedron Letters, Vol. 41, No. 6, pp. 919-922 (2000)
Zhang, H. C., et al., "Efficient synthesis of 3-substituted 2-arylindoles via Suzuki coupling reactions on the solid phase", Tetrahedron Letters, Vol. 42, No. 29, pp. 4751-4754 (2001)
Engler, T. A., et al., "Lewis Acid-Controlled Regioselectivity in Reactions of Styrenyl Systems with Benzoquinone Monoimides: New Regioselective Syntheses of Substituted 2-Aryl-2,3-dihydrobenzofurans, 2-Aryl-2,3-dihydroindoles, and 2-Arylindoles", J. Org. Chem., Vol. 61, No. 26, pp. 9297-9308 (1996)
Derwent Abstract No. 2003-221366/21, "Antihepatitis C agents comprise new and known fused cyclic compounds", Japan Tobacco Inc., Abstract of WO03/000254
Derwent Abstract No. 2001-514316/56, "New bicyclic compounds are hepatitis C polymerase inhibitors for treating and preventing hepatitis C", Japan Tobacco Inc., Abstract of WO01/47883

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**Examiner  
Signature**

/Sun Jae Loewe/

Date  
Considered

02/22/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.